Welcome back to Stockhouse Member Sign In
Sign in with one of the following accounts.
Send my password
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Use one of the following accounts.
This company is conducting a phase III clinical study of Kiacta which is expected to conclude next year. They are well funded and will...
I got out a 1.30 and licked my tax wounds.
It looks good, but how would an "exit" impact the company and stock? I've been quite long here.
Big things brewing at Bellus; Could an exit be on the horizon? Roberto Bellini, BELLUS Health president and CEO When BELLUS...